Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 30, 2021 - Issue 12
Submit an article Journal homepage
192
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Safety, tolerability, pharmacodynamics, and pharmacokinetics of CJC-1134-PC in healthy Chinese subjects and type-2 diabetic subjects

Yanhua Dinga Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China
,
Hong Zhanga Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China
,
Xiaoxue Zhua Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China
,
Min Wua Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, China
,
Lizhi Yangb Department of pharmacy, Maternal and Child Health and Family Planning Service Center of Changchun, Changchun, China
,
Zhiwen Yaoc Conjuchem LLC, Culver City, CA, USA
,
Qiang Xiec Conjuchem LLC, Culver City, CA, USA
,
Xiping Liuc Conjuchem LLC, Culver City, CA, USA
&
Cuiyun Lia Phase I Clinical Trial Unit, First Hospital, Jilin University, Changchun, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6306-2394
ORCID Icon show all
Pages 1241-1248 | Received 02 Jul 2021, Accepted 17 Nov 2021, Published online: 29 Nov 2021

References

  • Amanat S, Ghahri S, Dianatinasab A, et al. Exercise and type 2 diabetes. Adv Exp Med Biol. 2020;1228:91–105.
  • Amori RE, Lau J, Pittas AG. Effificacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194–206.
  • Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147:386–399.
  • Hu C, Jia W. Diabetes in China: epidemiology and genetic risk factors and their clinical utility in personalized medication. Diabetes. 2018;67(1):3–11.
  • Ma RC, Lin X, Jia W. Causes of type 2 diabetes in China. Lancet Diabetes Endocrinol. 2014;2:980–991.
  • Collins L, and Costello, RA. Glucagon-like Peptide-1 Receptor Agonists. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 https://www.ncbi.nlm.nih.gov/books/NBK551568/ .
  • Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 2002;122:531–544.
  • Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2:1300–1304.
  • Lutz TA, Osto E. Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism. Curr Opin Lipidol. 2016;27(3):257–263.
  • Reed J, Bain S, and Kanamarlapudi V. Recent advances in understanding the role of glucagon-like peptide 1. F1000Res. Published 2020Apr6.
  • Kim JG, Baggio LL, Bridon DP, et al. Development and characterization of a glucagon-like peptide 1- albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes. 2003;52:751–759.
  • Bucheit JD, Pamulapati LG, Carter N, et al. Oral semaglutide: a review of the first oral glucagon-like peptide 1 receptor agonist. Diabetes Technol Ther. 2020;22(1):10–18.
  • Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab. 2021;46:101090.
  • Tiessen RG, Castaigne JP, Dreyfus JF, et al. Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects. Int J Clin Pharmacol Ther. 2008;46(9):443–452.
  • Baggio LL, Huang Q, Cao X, et al. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology. 2008;134(4):1137–1147.
  • Wang M, Kipnes M, Matheson S, et al. Safety and pharmacodynamics of CJC-1134-PC, a novel GLP-1 receptor agonist, in subjects with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blind, dose escalation study. Diabetes. 2007;56:A133.
  • Wang M, Matheson S, Picard J, et al. PC-DAC (TM): exendin-4 (CJC-1134-PC) significantly reduces HbA1c and body weight as an adjunct therapy to metformin: two randomized, double-blind, placebo-controlled, 12 week, phase II studies in subjects with type 2 diabetes mellitus. Diabetes. 2009;58:A148.
  • Bush MA, Matthews JE, De Boever EH, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab. 2009;11(5):498–505.
  • Bettge K, Kahle M, Abd El Aziz MS, et al. Occurrence of nausea, vomit and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19(3):336–347.
  • Lowe PJ, Tannenbaum S, Wu K, et al. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin Pharmacol Toxicol. 2010;106(3):195–209.
  • Shi A, Xie P, Nielsen LL, et al. Pharmacokinetics, safety and tolerability of once-weekly subcutaneous semaglutide in healthy Chinese subjects: a double-blind, phase 1, randomized controlled trial. Adv Ther. 2021;38(1):550–561.
  • Larsen J, Hylleberg B, Ng K, et al. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic subjects who are poorly controlled on sulphonylurea treatment. Diabetes Care. 2001;24:1416–1421.
  • Kuwata H, Yabe D, Murotani K, et al. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: a prospective, observational study [published online ahead of print. J Diabetes Investig. 2021;May 22. DOI:https://doi.org/10.1111/jdi.13598.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.